Mr. Thomas Smeenk reports

HEMOSTEMIX ANNOUNCES PRIVATE PLACEMENT

Hemostemix Inc. has arranged a non-brokered private placement of $280,594 at 12.5 cents per share. Subject to the TSX Venture Exchange approval, the company will issue 2,244,752 shares.

As per TSX Venture Exchange Policy 4.1, the investor is arm's length to the company and is not a related party to the company at the time of disclosure.

The use of proceeds will be allocated to general working capital purposes, supporting the company's continuing operational expenses and business development activities.

The company confirms that there is no material fact or material change about the company that has not been generally disclosed.

All securities issued in connection with the offering are subject to a four-month hold period from the closing date under applicable Canadian securities laws in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside of Canada.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum technology pioneer award, the company has developed, has patented, is scaling and is selling autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, and potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer-reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase 2 clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 50 per cent in the CLTI patient population, University of British Columbia and University of Toronto reported to the 41st meeting of vascular surgeons: 0 per cent mortality, cessation of pain and wound healing in 83 per cent of patients followed for up to 4.5 years, as a midpoint result.

We seek Safe Harbor.